(Q34655579)

3 August 2017

title

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (English)

1 reference

Frédérique Penault-Llorca

3 August 2017

1 reference

ESMO Guidelines Working Group

3

object named as

F Penault-Llorca

0 references

8

object named as

ESMO Guidelines Working Group

1 reference

3 August 2017

E Senkus

1

1 reference

3 August 2017

S Kyriakides

2

1 reference

3 August 2017

P Poortmans

4

1 reference

3 August 2017

A Thompson

5

1 reference

3 August 2017

S Zackrisson

6

1 reference

3 August 2017

F Cardoso

7

1 reference

3 August 2017

publication date

22 August 2013

1 reference

3 August 2017

1 reference

3 August 2017

volume

24 Suppl 6

1 reference

3 August 2017

page(s)

vi7-23

1 reference

Behavioral risk factors in breast cancer: can risk be modified?

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Mammographic screening programmes in Europe: organization, coverage and participation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

The benefits and harms of breast cancer screening: an independent review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Assessing radiologist performance using combined digital mammography and breast tomosynthesis compared with digital mammography alone: results of a multicenter, multireader trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

ASCO-CAP Guidelines for Breast Predictive Factor Testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

FDG-PET/CT in the staging of local/regional metastases in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Quality indicators in breast cancer care

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

American Society of Clinical Oncology recommendations on fertility preservation in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

The challenges of success

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Effect of postoperative radiotherapy on autologous deep inferior epigastric perforator flap volume after immediate breast reconstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Radiotherapy for breast cancer in patients undergoing breast reconstruction or augmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Locoregional treatment of primary breast cancer: consensus recommendations from an International Expert Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Survival after lumpectomy and mastectomy for early stage invasive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Long-term results of hypofractionated radiation therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Post-operative radiotherapy for ductal carcinoma in situ of the breast--a systematic review of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Coprescription of tamoxifen and medications that inhibit CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Breast-cancer adjuvant therapy with zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Adjuvant chemotherapy in older women with early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Physical Activity and Survival After Breast Cancer Diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Weight loss in breast cancer patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Cancer prevalence estimates in Europe at the beginning of 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000-2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT284

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDT284

1 reference

3 August 2017

1 reference